We could not find any results for:
Make sure your spelling is correct or try broadening your search.
CEO Discusses Recent Stem Cell Breakthrough, Submission of Proposal to Department of Defense and Progress of Phase II Cancer Trial in Interview CLEVELAND, April 27 /PRNewswire-FirstCall/...
Date Change to June 12 CLEVELAND, April 4 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company will hold its 2007 annual stockholders...
CLEVELAND, March 26 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the ValueRich Small-Cap Financial Expo...
Company plans to submit Protectan CBLB502 for Department of Defense request for proposal for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome...
CLEVELAND, Feb. 8 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the Roth Capital Partners 19th Annual OC...
CLEVELAND, Feb. 6 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the BIO CEO and Investor Conference to be...
CLEVELAND, Feb. 5 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company was featured in an article in the February 5, 2007, issue of...
CLEVELAND, Jan. 23 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI) (BSE:CFB), today announced that Chief Scientist Andrei Gudkov, Ph.D., D. Sci., was interviewed by...
Company to Receive up to $5 Million of Non-dilutive Funding from Roswell Park and Various New York Agencies CLEVELAND, Jan. 12 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI...
CLEVELAND, Aug. 31 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (Nasdaq: CBLI; Boston Stock Exchange: CFB), today announced that the company is scheduled to present at the Roth Capital...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions